You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Evidences for the Anti-panic Actions of Cannabidiol
|
|---|---|
| Published in |
Current Neuropharmacology, February 2017
|
| DOI | 10.2174/1570159x14666160509123955 |
| Pubmed ID | |
| Authors |
Vanessa P. Soares, Alline C. Campos |
| Abstract |
Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with anti-anxiety properties that has been suggested as an alternative for treating anxiety disorders. In the present chapter, we included both experimental laboratory animal and human studies that have investigated the putative anti-panic properties of CBD. Taken together, the studies assessed in the present chapter clearly suggest an anxiolytic-like effect of CBD in both animal models and healthy volunteers. Novel clinical trials involving patients with the PD diagnosis, however, are clearly needed to clarify the specific mechanism of action of CBD and the safe and ideal therapeutic doses of this compound. |
X Demographics
The data shown below were collected from the profiles of 50 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 24% |
| Canada | 3 | 6% |
| France | 2 | 4% |
| South Africa | 2 | 4% |
| Mexico | 1 | 2% |
| Australia | 1 | 2% |
| Comoros | 1 | 2% |
| Japan | 1 | 2% |
| Saudi Arabia | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 23 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 38 | 76% |
| Practitioners (doctors, other healthcare professionals) | 6 | 12% |
| Science communicators (journalists, bloggers, editors) | 3 | 6% |
| Scientists | 3 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 22% |
| Student > Master | 7 | 12% |
| Other | 6 | 10% |
| Researcher | 4 | 7% |
| Student > Ph. D. Student | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 23 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Medicine and Dentistry | 6 | 10% |
| Neuroscience | 5 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Engineering | 3 | 5% |
| Other | 9 | 15% |
| Unknown | 28 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 169. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2024.
All research outputs
#243,291
of 25,769,258 outputs
Outputs from Current Neuropharmacology
#18
of 943 outputs
Outputs of similar age
#5,281
of 428,203 outputs
Outputs of similar age from Current Neuropharmacology
#1
of 21 outputs
Altmetric has tracked 25,769,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 943 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 428,203 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.